Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
Identifieur interne : 000557 ( Main/Exploration ); précédent : 000556; suivant : 000558Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
Auteurs : Nitesh Sanghai [Canada] ; Kashfia Shafiq [Canada] ; Geoffrey K. Tranmer [Canada]Source :
- Mini reviews in medicinal chemistry [ 1875-5607 ] ; 2021.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (pharmacologie), AMP (usage thérapeutique), Alanine (analogues et dérivés), Alanine (pharmacologie), Alanine (usage thérapeutique), Animaux (MeSH), Antipaludiques (pharmacologie), Antipaludiques (usage thérapeutique), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Chloroquine (pharmacologie), Chloroquine (usage thérapeutique), Découverte de médicament (méthodes), Humains (MeSH), Hydroxychloroquine (pharmacologie), Hydroxychloroquine (usage thérapeutique), Repositionnement des médicaments (méthodes).
- MESH :
- analogues et dérivés : AMP, Alanine.
- méthodes : Découverte de médicament, Repositionnement des médicaments.
- pharmacologie : AMP, Alanine, Antipaludiques, Antiviraux, Chloroquine, Hydroxychloroquine.
- usage thérapeutique : AMP, Alanine, Antipaludiques, Antiviraux, Chloroquine, Hydroxychloroquine.
- Animaux, Humains.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (pharmacology), Adenosine Monophosphate (therapeutic use), Alanine (analogs & derivatives), Alanine (pharmacology), Alanine (therapeutic use), Animals (MeSH), Antimalarials (pharmacology), Antimalarials (therapeutic use), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), Chloroquine (pharmacology), Chloroquine (therapeutic use), Drug Discovery (methods), Drug Repositioning (methods), Humans (MeSH), Hydroxychloroquine (pharmacology), Hydroxychloroquine (therapeutic use), SARS-CoV-2 (drug effects).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , pharmacology : Adenosine Monophosphate, Alanine, Antimalarials, Antiviral Agents, Chloroquine, Hydroxychloroquine.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Antimalarials, Antiviral Agents, Chloroquine, Hydroxychloroquine.
- drug effects : SARS-CoV-2.
- drug therapy : COVID-19.
- methods : Drug Discovery, Drug Repositioning.
- Animals, Humans.
Abstract
Due to the rapidly developing nature of the current COVID-19 outbreak and its almost immediate humanitarian and economic toll, coronavirus drug discovery efforts have largely focused on generating potential COVID-19 drug candidates as quickly as possible. Globally, scientists are working day and night to find the best possible solution to treat the deadly virus. During the first few months of 2020, the SARS-CoV-2 outbreak quickly developed into a pandemic, with a mortality rate that was increasing at an exponential rate day by day. As a result, scientists have turned to a drug repurposing approach to rediscover the potential use and benefits of existing approved drugs. Currently, there is no single drug approved by the U.S. Food and Drug Administration (FDA), for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously known as 2019-nCoV) that causes COVID-19. Based on only in-vitro studies, several active drugs are already in the clinical pipeline, made possible by following the compassionate use of medical protocols. This method of repurposing and the use of existing molecules like Remdesivir (GS-5734), Chloroquine, Hydroxychloroquine, etc. has proven to be a landmark in the field of drug rediscovery. In this review article, we will discuss the repurposing of medicines for treating the deadly novel coronavirus (SARS-CoV-2).
DOI: 10.2174/1389557520999200824103803
PubMed: 32838716
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.</title><author><name sortKey="Sanghai, Nitesh" sort="Sanghai, Nitesh" uniqKey="Sanghai N" first="Nitesh" last="Sanghai">Nitesh Sanghai</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy, Rady Faculty of Health Science, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>College of Pharmacy, Rady Faculty of Health Science, University of Manitoba, Winnipeg, MB R3E 0T5</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Shafiq, Kashfia" sort="Shafiq, Kashfia" uniqKey="Shafiq K" first="Kashfia" last="Shafiq">Kashfia Shafiq</name><affiliation wicri:level="4"><nlm:affiliation>Department of Human Anatomy and Cell Science, Faculty of Science, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Human Anatomy and Cell Science, Faculty of Science, University of Manitoba, Winnipeg, MB R3T 2N2</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Tranmer, Geoffrey K" sort="Tranmer, Geoffrey K" uniqKey="Tranmer G" first="Geoffrey K" last="Tranmer">Geoffrey K. Tranmer</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy, Rady Faculty of Health Science, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>College of Pharmacy, Rady Faculty of Health Science, University of Manitoba, Winnipeg, MB R3E 0T5</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:32838716</idno><idno type="pmid">32838716</idno><idno type="doi">10.2174/1389557520999200824103803</idno><idno type="wicri:Area/Main/Corpus">000D98</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D98</idno><idno type="wicri:Area/Main/Curation">000D98</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000D98</idno><idno type="wicri:Area/Main/Exploration">000D98</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.</title><author><name sortKey="Sanghai, Nitesh" sort="Sanghai, Nitesh" uniqKey="Sanghai N" first="Nitesh" last="Sanghai">Nitesh Sanghai</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy, Rady Faculty of Health Science, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>College of Pharmacy, Rady Faculty of Health Science, University of Manitoba, Winnipeg, MB R3E 0T5</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Shafiq, Kashfia" sort="Shafiq, Kashfia" uniqKey="Shafiq K" first="Kashfia" last="Shafiq">Kashfia Shafiq</name><affiliation wicri:level="4"><nlm:affiliation>Department of Human Anatomy and Cell Science, Faculty of Science, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Human Anatomy and Cell Science, Faculty of Science, University of Manitoba, Winnipeg, MB R3T 2N2</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Tranmer, Geoffrey K" sort="Tranmer, Geoffrey K" uniqKey="Tranmer G" first="Geoffrey K" last="Tranmer">Geoffrey K. Tranmer</name><affiliation wicri:level="4"><nlm:affiliation>College of Pharmacy, Rady Faculty of Health Science, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>College of Pharmacy, Rady Faculty of Health Science, University of Manitoba, Winnipeg, MB R3E 0T5</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author></analytic><series><title level="j">Mini reviews in medicinal chemistry</title><idno type="eISSN">1875-5607</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Adenosine Monophosphate (pharmacology)</term><term>Adenosine Monophosphate (therapeutic use)</term><term>Alanine (analogs & derivatives)</term><term>Alanine (pharmacology)</term><term>Alanine (therapeutic use)</term><term>Animals (MeSH)</term><term>Antimalarials (pharmacology)</term><term>Antimalarials (therapeutic use)</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>Chloroquine (pharmacology)</term><term>Chloroquine (therapeutic use)</term><term>Drug Discovery (methods)</term><term>Drug Repositioning (methods)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (pharmacology)</term><term>Hydroxychloroquine (therapeutic use)</term><term>SARS-CoV-2 (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term><term>AMP (pharmacologie)</term><term>AMP (usage thérapeutique)</term><term>Alanine (analogues et dérivés)</term><term>Alanine (pharmacologie)</term><term>Alanine (usage thérapeutique)</term><term>Animaux (MeSH)</term><term>Antipaludiques (pharmacologie)</term><term>Antipaludiques (usage thérapeutique)</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Chloroquine (pharmacologie)</term><term>Chloroquine (usage thérapeutique)</term><term>Découverte de médicament (méthodes)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (pharmacologie)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Repositionnement des médicaments (méthodes)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Antimalarials</term><term>Antiviral Agents</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Antimalarials</term><term>Antiviral Agents</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term><term>Alanine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Discovery</term><term>Drug Repositioning</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Découverte de médicament</term><term>Repositionnement des médicaments</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>AMP</term><term>Alanine</term><term>Antipaludiques</term><term>Antiviraux</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term><term>Alanine</term><term>Antipaludiques</term><term>Antiviraux</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Due to the rapidly developing nature of the current COVID-19 outbreak and its almost immediate humanitarian and economic toll, coronavirus drug discovery efforts have largely focused on generating potential COVID-19 drug candidates as quickly as possible. Globally, scientists are working day and night to find the best possible solution to treat the deadly virus. During the first few months of 2020, the SARS-CoV-2 outbreak quickly developed into a pandemic, with a mortality rate that was increasing at an exponential rate day by day. As a result, scientists have turned to a drug repurposing approach to rediscover the potential use and benefits of existing approved drugs. Currently, there is no single drug approved by the U.S. Food and Drug Administration (FDA), for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously known as 2019-nCoV) that causes COVID-19. Based on only in-vitro studies, several active drugs are already in the clinical pipeline, made possible by following the compassionate use of medical protocols. This method of repurposing and the use of existing molecules like Remdesivir (GS-5734), Chloroquine, Hydroxychloroquine, etc. has proven to be a landmark in the field of drug rediscovery. In this review article, we will discuss the repurposing of medicines for treating the deadly novel coronavirus (SARS-CoV-2).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32838716</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-5607</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Mini reviews in medicinal chemistry</Title><ISOAbbreviation>Mini Rev Med Chem</ISOAbbreviation></Journal><ArticleTitle>Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.</ArticleTitle><Pagination><MedlinePgn>3-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1389557520999200824103803</ELocationID><Abstract><AbstractText>Due to the rapidly developing nature of the current COVID-19 outbreak and its almost immediate humanitarian and economic toll, coronavirus drug discovery efforts have largely focused on generating potential COVID-19 drug candidates as quickly as possible. Globally, scientists are working day and night to find the best possible solution to treat the deadly virus. During the first few months of 2020, the SARS-CoV-2 outbreak quickly developed into a pandemic, with a mortality rate that was increasing at an exponential rate day by day. As a result, scientists have turned to a drug repurposing approach to rediscover the potential use and benefits of existing approved drugs. Currently, there is no single drug approved by the U.S. Food and Drug Administration (FDA), for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously known as 2019-nCoV) that causes COVID-19. Based on only in-vitro studies, several active drugs are already in the clinical pipeline, made possible by following the compassionate use of medical protocols. This method of repurposing and the use of existing molecules like Remdesivir (GS-5734), Chloroquine, Hydroxychloroquine, etc. has proven to be a landmark in the field of drug rediscovery. In this review article, we will discuss the repurposing of medicines for treating the deadly novel coronavirus (SARS-CoV-2).</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanghai</LastName><ForeName>Nitesh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Rady Faculty of Health Science, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafiq</LastName><ForeName>Kashfia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Human Anatomy and Cell Science, Faculty of Science, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tranmer</LastName><ForeName>Geoffrey K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Rady Faculty of Health Science, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mini Rev Med Chem</MedlineTA><NlmUniqueID>101094212</NlmUniqueID><ISSNLinking>1389-5575</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Drug discovery</Keyword><Keyword MajorTopicYN="N">Drug repurposing</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">WHO</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32838716</ArticleId><ArticleId IdType="pii">MRMC-EPUB-109436</ArticleId><ArticleId IdType="doi">10.2174/1389557520999200824103803</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Manitoba</li></region><settlement><li>Winnipeg</li></settlement><orgName><li>Université du Manitoba</li></orgName></list><tree><country name="Canada"><region name="Manitoba"><name sortKey="Sanghai, Nitesh" sort="Sanghai, Nitesh" uniqKey="Sanghai N" first="Nitesh" last="Sanghai">Nitesh Sanghai</name></region><name sortKey="Shafiq, Kashfia" sort="Shafiq, Kashfia" uniqKey="Shafiq K" first="Kashfia" last="Shafiq">Kashfia Shafiq</name><name sortKey="Tranmer, Geoffrey K" sort="Tranmer, Geoffrey K" uniqKey="Tranmer G" first="Geoffrey K" last="Tranmer">Geoffrey K. Tranmer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000557 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000557 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32838716
|texte= Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32838716" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |